Publications:

Selected presentations by Senopsys staff include:

  • Food And Drug Administration invited Speaker “Defining ‘Candy-Like’ Nonprescription Drug Products”. FDA ONPD Public Meeting. October 30, 2023
  • “Selecting Excipients for Improved Drug Palatability”. ExciPerience Conference. September 14, 2023
  • “Innovations and Advances in Drug Dosage Forms”. Drug Solutions Podcast. August 1, 2023
  • “Taste Assessment and Optimization of Oral Formulations” October 27, 2022 NJPhAST Meeting.
  • “Taste Masking as an Alternative to Improve Patient Convenience and Compliance” (BASF, Glatt & Senopsys LLC.), November, 2020 AAPS PharmSci 360 Annual Meeting.
  • “Sensory Evaluation of Norvir® (Ritonavir) 100 mg Powder for Special Populations” (AbbVie Inc. & Senopsys LLC.), November, 2019 AAPS PharmSci 360 Annual Meeting.
  • “The Science of Taste Perception and Sensory Analysis” (Symposia on Pediatric Drug Products), 2017 AAPS Annual Meeting – San Diego, CA. [Presentation Here]
  • “Development Strategies for Age-Appropriate Pediatric Drug Products”,  2017 Joint Meeting of the Southern California Pharmaceutical Discussion Group / Southern California American Chemical Society  (SCPDG/SDACS) 
  • “A Structured Taste Masking Process for Developing Palatable Pediatric Chewable Tablets”,  2017 Northeast Regional Discussion Group Annual Meeting
  • “Developing Palatable Drug Products: It’s More than Yuck and Yum”,  2017 AAPS Bay Area Discussion Group
  • “A Structured Taste Masking Process for Developing Palatable Pediatric Chewable Tablets” (Bristol-Myers Squibb), 2016 AAPS Annual Meeting.
  • “Flavor Profile Method of Descriptive Sensory Analys Development of a Solithromycin Pediatric Powder for Oral Suspension Formulation” (Cempra Inc. & Toyama Chemical Co., Ltd), 2015 AAPS Annual Meeting.
  • “Developing Palatable Pediatric Formulations”, Pediatric Formulations Development Workshop, ACCP Annual Meeting September 2013.
  • “Framework for Developing Palatable Paediatric Drug Products – The Tools and Approaches for Taste Masking” Global Research in Paediatrics (GRiP) 4th “Meet the Expert” on Paediatric Formulations, June 2013.
  • “Development of Apixaban Oral Solution Formulation: Excipients and Palatability.” (Bristol-Myers Squibb), 2013 ASCPT Annual Meeting.
  • “Sensory-directed Taste Optimization of Pediatric Drug Products”(Guest Lecture), Concordia School of Pharmacy January 2013.
  • “Sensory-directed Taste Optimization of Pediatric Drug Products”(Short Course), 2010 AAPS Annual Meeting.
  • “Taste Effects of Excipients Used in the Solubilization of Hydrophobic Drugs”, April, 2010 AAPS Northeast Regional Discussion Group.
  • “Pediatric Drug Delivery: Formulating Better Medicines for Children” (With Dr. Susan Lum of Patheon Inc.), February, 2010 New Jersey Pharmaceutical Association for Science and Technology Meeting.
  • “An Investigation of the Relationship Between Eszopiclone Tablet Coating and Initial Dysgeusia Using the Flavor Profile Method” (Sepracor), 2009 AAPS Annual Meeting.
  • “Development of a Palatable, Oral Solution of Tolevamer™” (Genzyme), 2006 AAPS Annual Meeting.
  • “The Development of Palatable Pediatric Formulations – Establishing the Target, Measuring Progress and Verifying Acceptability,” Pre-Clinical and Clinical Strategies for Pediatric Drug Development, February 2006.
  • “Developing Palatable Pharmaceuticals,” SRI Drug Delivery Technologies and Deal Making Summit, September 2005.
  • “A Sensory Panel Method for Measuring the Mouthfeel Characteristics and Ease-of-swallowing of Film Coated Tablets” (Colorcon), 2004 AAPS Annual Meeting.
  • “Development of a Palatable Oral Suspension Containing Tenofovir Disoproxil Fumarate” (Gilead Sciences), 2003 AAPS Annual Meeting.
  • “Development of a Palatable Oral Suspension Dosage form of Cefditoren Pivoxil” (TAP Pharmaceuticals), 2002 AAPS Annual Meeting.
  • “Development of a Palatable Stable Pediatric Oral Suspension Containing Emivirine” (Triangle Laboratories), 2000 AAPS Annual Meeting.
  • “Development of a Palatable, Oral Liquid Drug Product for Sodium n-(8-[2-hydroxybenzoyl]-amino) caprylate (SNAC) and Heparin Sodium” (Emisphere Technologies), 1999 AAPS Annual Meeting.